We are investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.
Upon this news, HROW’s stock price fell 23.69% in trading on May 12, 2026. In particular, on HROW’s quarterly earnings call on May 12, several analysts inquired into the gross-to-net adjustment.
If you are or were a HROW shareholder and have suffered losses, you may contact us to discuss your legal rights and options at no charge by completing and submitting the form below.